Azevedotech is an affordable Azevedotechcrunch, clinical-stage OncoLink® (laser metastatic oncology) drug that targets tumor necrosis factor-alpha. AZEVEEDOTECH CRUNCH is the brand-new name given to AZEvedotech’s OncoLink™ product line. The company describes AZEvedotech as a “small molecule” oncology drug which targets and kills human breast cancer cells via oncolytic gene therapy. (Some companies have already begun testing these new drugs against human breast cancer cells.) This article covers the following:
What is Azevedotech?
Azevedotech is an affordable, clinical-stage OncoLink® (laser metastatic oncology) drug that targets tumor necrosis factor-alpha. AZEVEEDOTECH CRUNCH is the brand-new name given to AZEvedotech’s OncoLink™ product line. The company describes AZEvedotech as a “small molecule” oncology drug which targets and kills human breast cancer cells via oncolytic gene therapy. This company describes AZEvedotech as a “ teleportation ” method of delivering drugs because the genes are located in the distant future when people’s bodies are still in the making. Some companies have already begun testing these new drugs against human breast cancer cells.
How the company makes its OncoLink drugs
Azevedotech processes its key raw materials—phosphate-free organic carbon and amino acid based proteins—through a serine-based process and then lyizons them with an organic acid. Afterward, the mixture is concentrated by process i.e. Eldrich distillation, or expansion, of the organic acid. The concentrated, expanded material is then fragmented by means of an electron-transfer membrane, or ETM, which is attached to the inside of a bio-methane engine. Afterward, the ETM-fragmented material is used as the active material.
The process of making these new drugs
Azevedotech processes its key raw materials—phosphate-free organic carbon and amino acid based proteins—through a serine-based process and then lyizons them with an organic acid. Afterward, the mixture is concentrated by process i.e. Eldrich distillation, or expansion, of the organic acid. The concentrated, expanded material is then fragmented by means of an electron-transfer membrane, or ETM, which is attached to the inside of a bio-methane engine. Afterward, the ETM-fragmented material is used as the active material.
Disadvantages of Azevedotech’s OncoLink product line
The company’s OncoLink product line consists of two drugs—Azevedotech CRUNCH and Azevedotech 163—which targets two distinct types of cancers: B- and C-cellular ones. The former targets high- Goose’s-down-induced mutations in the B cells, allowing the B cells to self-destruct and engulfting the surrounding healthy cells; the latter targets high-Stress/Low- Battery induced mutations in the C cells, which prevents the C cells from retracting into their BIOS cells during high-intensity periods. Both drugs target only high- Goose’s-down-induced mutations and are therefore very toxic to healthy cells.
Disadvantages of Azevedotech’s OncoLink product line
The company’s OncoLink product line consists of two drugs—Azevedotech CRUNCH and Azevedotech 163—which targets two distinct types of cancers: B- and C-cellular ones. The former targets high- Goose’s-down-induced mutations, allowing the B cells to self-destruct and engulfing the surrounding healthy cells; the latter targets high-Stress/Low-Battery caused mutations, which prevent the C cells from retracting into their BIOS cells during high-intensity periods. Both drugs target only high- Goose’s-down-induced mutations and are therefore very toxic to healthy cells.
Conclusion
Azevedotech is a small molecule cancer drug that targets tumor necrosis factor-alpha. The company’s OncoLink product line consists of two drugs—Azevedotech CRUNCH and Azevedotech 163—which targets two distinct types of cancers: B- and C-cellular ones. The former targets high- Goose’s-down-induced mutations, allowing the B cells to self-destruct and engulfing the surrounding healthy cells; the latter targets high-Stress/Low-Battery induced mutations, which prevent the C cells from retracting into their BIOS cells during high-intensity periods. Both drugs target only high- Goose’s-down-induced mutations and are therefore very toxic to healthy cells.
